share_log

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target

Benzinga ·  Apr 11 10:53

HC Wainwright & Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $19 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
1
Comment Comment · Views 340

Recommended

Write a comment